According to the World Health Organization (WHO), more than 6 million new cancer cases are diagnosed in Asia every year. Cancer is the leading cause of death and the incidence rates are increasing annually. Due to this, the demand for quality cancer treatments has risen dramatically, which is contributing to the growth of the market.
Asia-Pacific Cancer Therapy Market-Market Dynamics
The end-users of this market are clinics, hospitals, and research centers. Lung cancer, breast cancer, colorectal cancer, ovarian cancer, head & neck cancer, stomach cancer and liver cancer are some of the common cancers increasing the treatment options in Asia.
Increasing incidence of cancer
Growing demand for advanced therapies
Patent expiry of leading drugs
Increasing public awareness about diseases and treatment options
High prices of therapies
Side-effects caused during treatment
Change in reimbursement policies
The market for cancer therapy in Asia-Pacific is segmented based on the type of therapy, which includes chemotherapy (marketed drugs and drugs in the pipeline), radiotherapy, surgery, hormone therapy, targeted cancer therapy, immunotherapy (monoclonal antibodies, cancer vaccines, and non-specific immunotherapy) and combination therapy. Chemotherapy, radiation therapy, and combinational therapy are increasingly available in the Asia-Pacific region. However, chemotherapy is the largest segment of APAC cancer therapeutics market.
Many players in this market are trying to expand their product portfolio in order to top the global market. While a few companies are entering the market by acquisitions, top companies are expanding their growth by acquiring other companies. Some companies have adopted product innovation and new product launches as their key business strategy to ensure their dominance in this market. Roche is developing a large number of combinational therapies.
Market analysis for the Asia-Pacific cancer therapy market, with region-specific assessments and competition analysis on the global and regional scale.
Market definition along with the identification of key drivers and restraints.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their market share.
Identification and analysis of the macro and micro factors that affect the Asia-Pacific cancer therapy market on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.
Insights on the major countries/regions in which this industry is growing and to also identify the regions that are still untapped.
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
2. Research Methodology
2.2 Analysis Methodology
2.3 Econometric Forecast Model
2.4 Research Assumptions
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
5.1 Current Market Scenario
5.2 Applications of Cancer therapeutics
5.3 Technology Overview
5.4 New Developments
5.5 Industry Value-Chain Analysis
5.6 Product Life-Cycle Analysis
5.7 Product Benchmarking
5.8 Investment Analysis
5.9 PorterFive Forces
5.9.1 Bargaining Power of Suppliers
5.9.2 Bargaining Power of Consumers
5.9.3 Threat of New Entrants
5.9.4 Threat of Substitute Products and Services
5.9.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
7. Market Drivers
7.1 Increased Incidence of Cancer
7.2 Increasing Public Awareness about Diseases and Treatment Options
7.3 Aging Population
7.4 Rising Government Initiatives
7.5 Growing Demand for Advanced Therapies
7.6 Patent Expiry of Leading Drugs
8. Market Restraints
8.1 High Prices of Therapies
8.2 Side-Effects Caused During Treatment
8.3 Change in Reimbursement Policies
8.4 Stringent Regulatory Issues
9. Key Challenges
10. Current Opportunities in the Market
11. Market Segmentation
11.1 By Type
220.127.116.11 Marketed Drugs
18.104.22.168 Drugs in Pipeline
11.1.3 Hormone Therapy
11.1.4 Targeted Cancer Therapy
22.214.171.124 Monoclonal Antibodies
126.96.36.199 Cancer Vaccines
188.8.131.52 Non-Specific Immunotherapy
11.1.6 Combination Therapy
11.2 By Disease
11.2.1 Lung Cancer
11.2.2 Breast Cancer
11.2.3 Colorectal Cancer
11.2.4 Ovarian Cancer
11.2.5 Head and Neck Cancer
11.2.6 Stomach Cancer
11.2.7 Liver Cancer
11.3 By End-User
11.3.3 Research Centers
11.4 By Geography
184.108.40.206 Australia & New Zealand
220.127.116.11 South Korea
12. Competitive Landscape
12.1 Merger and Acquisition Analysis
12.2 New Product Launches
12.3 Agreements, Collaborations & Partnerships
13. Company Profiles
13.3 Bristol-Myers Squibb
13.8 Astra Zeneca
14. Analyst Outlook for Investment Opportunities
15. Future Outlook of the Market